Clinical Trial Detail

NCT ID NCT04210115
Title Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Cisplatin + Fluorouracil + Pembrolizumab

Fluorouracil + Leucovorin + Oxaliplatin

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Cisplatin + Fluorouracil

Age Groups: adult senior

No variant requirements are available.